|
Recent Developments |
|
11-JUN-12
Credit rating agency, ICRA has reaffirmed the A rating on the Rs 1.5 billion, Non Convertible Debenture (NCD) programme of Arch Pharmalabs (APL). ICRA has also assigned an A rating to the Rs 1.5 billion additional NCD programme of APL.
07-OCT-10
Credit rating agency, ICRA has reaffirmed the short-term rating of A1 on the commercial paper/ short term debt programme of Arch Pharmalabs (APL) for Rs 1.5 billion (enhanced from Rs 1 billi... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 31-Mar-2007 (12) | 31-Mar-2006 (12) | 31-Mar-2005 (12) | | Net sales | 3625.52 | 2468.27 | 1555.03 | | Other Income | 11.17 | 1.36 | 2.52 | | Total Income | 3636.69 | 2469.63 | 1557.55 | | Cost of goods sold | 2930.25 | 2004.16 | 1272.37 | | OPBDIT | 706.44 | 465.47 | 285.18 | | PAT | 301.65 | 159.13 | 102.33 | | Gross Block | 2081.80 | 1395.17 | 892.29 | | Equity capital | 160.87 | 136.87 | 131.71 | | EPS (Rs.) | 18.75 | 11.63 | 7.48 | | DPS (Rs.) | 0.00 | 0.00 | 0.00 | | BV (Rs.) | 105.67 | 59.39 | 46.00 | | P/E range (x) | NA | NA | NA | | Debt / Equity (x) | 1.75 | 2.30 | 1.77 | | Operating margin (% of OI) | 19.4 | 18.8 | 18.3 | | Net margin (% of OI) | 8.3 | 6.4 | 6.6 |
|
|
Detailed Financials
|
|
|
|
|
